NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include: $RPRX, $ABEO, $AGEN
RPRX: Float of 37.18 million shares. The company had a Net Income growth of 48.6% in the last quarter. The price of RPRX has surged by over 150% on October 8 - 9th. After dropping substantially over the past week, it popped again on Friday and now is at the 38.2% Fib Retracement.
Right now, it's not compliant with Nasdaq. The price movement may be an attempt to get it to $1.00 very soon. Keep watching it.
ABEO: Float of 28.57 million shares with 19.13% short. On October 19th, the company announced the closing of its underwritten public offering with a gross offering size of approximately $92 million, which includes the full exercise of the underwriters’ option to purchase 750,000 additional shares, at the public offering price of $16.00 per share. On October 20th, this news had a positive effect sending the price up by 7%. The chart has been showing a nice upward trend since mid-June.
AGEN: Float of 51.51 million shares with 16.74% short. On Friday evening, the company announced today that the USFDA granted marketing authorization to GlaxoSmithKline's (GSK) herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon®. SHINGRIX is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older. The addition of QS-21 Stimulon helps improve the vaccine's effectiveness by boosting immune response in older adults who often experience age-related decline in immunity. Shingles is a major public health issue in the US, impacting as many as 1 in 3 older adults over the age of 50 years. Shingles is caused by a virus called varicella zoster, which is also known as the chicken pox virus. Nearly all older adults have the varicella zoster virus dormant in their nervous system waiting to reactivate with advancing age and weakened immune systems.
In addition, the company will be speaking at the Meeting of the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention in Atlanta, Georgia on Wednesday, October 25th at 8:15am.